Leadership and Strategy

Resilience Partners with Takeda's Plasma-Derived Therapies Business Unit on Multi-Product Development and Manufacturing

On February 15, National Resilience, Inc. (Resilience), a technology-focused manufacturing firm devoted to expanding access to complicated medications, signed a deal with Takeda's Plasma-Derived Therapies Business Unit to provide manufacturing services.

As part of the deal, Resilience will assist in developing and manufacturing numerous products in Takeda's plasma-derived pharmaceuticals portfolio from its plant in Mississauga, Ontario.

 "I'm proud to establish this relationship with Takeda, a company that has been pioneering plasma-derived therapies for more than 75 years. By bringing new technologies and innovation to biomanufacturing, we aim to help companies like Takeda reach more patients in need."

-Rahul Singhvi, Sc.D., and Chief Executive Officer of Resilience

In Mississauga, Resilience's 136,000 square foot (12,800 square meters) biomanufacturing plant provides process and analytical development, scale-up, drug substance, and drug product/fill manufacturing for various pharmaceuticals.

"Takeda is delighted to form this strategic collaboration with Resilience, leveraging their expertise in both plasma therapy development and manufacturing to complement our current infrastructure and capabilities,We will be able to use our combined resources to help us grow our portfolio, drive innovation, and help more patients around the world benefit from plasma medicines."

-Andreas Liebminger, Head of Pharmaceutical Sciences and Devices for the Plasma-Derived Therapies Business Unit at Takeda.